Murugan Dhanashree, Murugesan Vasanth, Panchapakesan Balaji, Rangasamy Loganathan
School of Biosciences & Technology (SBST), Vellore Institute of Technology (VIT), Vellore 632014, India.
Drug Discovery Unit (DDU), Centre for Biomaterials, Cellular and Molecular Theranostics (CBCMT), Vellore Institute of Technology (VIT), Vellore 632014, India.
Cancers (Basel). 2022 Nov 4;14(21):5438. doi: 10.3390/cancers14215438.
Natural killer (NK) cells are one of the first lines of defense against infections and malignancies. NK cell-based immunotherapies are emerging as an alternative to T cell-based immunotherapies. Preclinical and clinical studies of NK cell-based immunotherapies have given promising results in the past few decades for hematologic malignancies. Despite these achievements, NK cell-based immunotherapies have limitations, such as limited performance/low therapeutic efficiency in solid tumors, the short lifespan of NK cells, limited specificity of adoptive transfer and genetic modification, NK cell rejection by the patient's immune system, insignificant infiltration of NK cells into the tumor microenvironment (TME), and the expensive nature of the treatment. Nanotechnology could potentially assist with the activation, proliferation, near-real time imaging, and enhancement of NK cell cytotoxic activity by guiding their function, analyzing their performance in near-real time, and improving immunotherapeutic efficiency. This paper reviews the role of NK cells, their mechanism of action in killing tumor cells, and the receptors which could serve as potential targets for signaling. Specifically, we have reviewed five different areas of nanotechnology that could enhance immunotherapy efficiency: nanoparticle-assisted immunomodulation to enhance NK cell activity, nanoparticles enhancing homing of NK cells, nanoparticle delivery of RNAi to enhance NK cell activity, genetic modulation of NK cells based on nanoparticles, and nanoparticle activation of NKG2D, which is the master regulator of all NK cell responses.
自然杀伤(NK)细胞是抵御感染和恶性肿瘤的第一道防线之一。基于NK细胞的免疫疗法正在成为基于T细胞的免疫疗法的替代方案。在过去几十年中,基于NK细胞的免疫疗法的临床前和临床研究在血液系统恶性肿瘤方面取得了令人鼓舞的结果。尽管取得了这些成就,但基于NK细胞的免疫疗法仍存在局限性,例如在实体瘤中的性能有限/治疗效率低、NK细胞寿命短、过继转移和基因修饰的特异性有限、患者免疫系统对NK细胞的排斥、NK细胞向肿瘤微环境(TME)的浸润不足以及治疗费用高昂。纳米技术有可能通过引导NK细胞的功能、近实时分析其性能以及提高免疫治疗效率来协助激活、增殖、近实时成像并增强NK细胞的细胞毒性活性。本文综述了NK细胞的作用、其杀伤肿瘤细胞的作用机制以及可作为信号传导潜在靶点的受体。具体而言,我们综述了纳米技术可提高免疫治疗效率的五个不同领域:纳米颗粒辅助免疫调节以增强NK细胞活性、纳米颗粒增强NK细胞的归巢、纳米颗粒递送RNAi以增强NK细胞活性、基于纳米颗粒的NK细胞基因调节以及纳米颗粒激活NKG2D,NKG2D是所有NK细胞反应的主要调节因子。